Elucidating the neuropathological and molecular heterogeneity of amyloid beta and tau in Alzheimer’s disease through machine learning and transcriptomic integration

by Clinical Neuropsychologist Online | Wednesday, August 26, 2026 | Dementia

Abstract INTRODUCTION Functional brain network alterations associated with Alzheimer’s disease (AD) pathology, including amyloid beta (Aβ) and phosphorylated tau (p-tau), are difficult to interpret due to overlapping aging-associated and non-amyloid biological...

Estimating treatment effects in clinical studies of Alzheimer’s disease: What are estimands and why do we need them?

by Clinical Neuropsychologist Online | Wednesday, August 26, 2026 | Dementia

Abstract In clinical studies, it is scientifically important, and a regulatory expectation, that objectives be translated into key clinical questions by specifically defining treatment effects to be estimated. Estimands are part of a structured framework, as presented...

Hormone replacement therapy and dementia risk among postmenopausal women: Identifying responsive subgroups in the UK Biobank

by Clinical Neuropsychologist Online | Wednesday, August 26, 2026 | Dementia

Abstract INTRODUCTION Modifiers of the association between hormone replacement therapy (HRT) use and dementia risk and responsive subgroups, are unknown. METHODS In 183,450 postmenopausal women from the UK Biobank (mean 13.3 years follow-up), multivariable Cox...

APOE‐guided lecanemab dosing dissociates ARIA‐E from ARIA‐H: The K‐ROAD study

by Clinical Neuropsychologist Online | Wednesday, August 26, 2026 | Dementia

Abstract INTRODUCTION We evaluated whether apolipoprotein E (APOE εε4) genotype-guided lecanemab escalation mitigates the APOE εε4–driven amyloid-related imaging abnormalities (ARIA) with edema (ARIA-E) gradient and whether ARIA-E and ARIA with hemosiderin deposition...

Chronic stress, social support, and domain‐specific cognitive decline in HABS‐HD

by Clinical Neuropsychologist Online | Wednesday, August 26, 2026 | Dementia

Abstract INTRODUCTION Few studies have examined the longitudinal associations between chronic stress, social support, and cognitive decline or whether sociodemographic factors modify associations. METHODS We included 3873 older adults enrolled in the Health and Aging...

When treatment becomes risk: polypharmacy and inappropriate prescribing in cognitive impairment in 2379 consecutive patients from a memory clinic

by Clinical Neuropsychologist Online | Tuesday, August 25, 2026 | Dementia

Abstract BACKGROUND Polypharmacy, potentially inappropriate medications (PIMs), and drugs associated with drug-induced cognitive impairment (DICI) are highly prevalent in older adults and may affect cognitive decline. METHODS This observational retrospective study...